Avid Bioservices, Inc. (CDMO)
USD 12.49
(0.0%)
USD 12.49
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 169.72 Million USD | 12.63% |
| 2023 | 150.69 Million USD | 167.38% |
| 2022 | 56.35 Million USD | 208.97% |
| 2021 | -51.72 Million USD | -449.59% |
| 2020 | -9.41 Million USD | 70.83% |
| 2019 | -32.25 Million USD | 23.68% |
| 2018 | -42.26 Million USD | 9.69% |
| 2017 | -46.79 Million USD | 23.8% |
| 2016 | -61.41 Million USD | 9.69% |
| 2015 | -68 Million USD | 12.25% |
| 2014 | -77.49 Million USD | -120.12% |
| 2013 | -35.2 Million USD | -95.22% |
| 2012 | -18.03 Million USD | 17.1% |
| 2011 | -21.75 Million USD | -32.06% |
| 2010 | -16.47 Million USD | -209.41% |
| 2009 | -5.32 Million USD | 64.71% |
| 2008 | -15.08 Million USD | 2.66% |
| 2007 | -15.49 Million USD | 4.29% |
| 2006 | -16.19 Million USD | -77.01% |
| 2005 | -9.14 Million USD | 38.54% |
| 2004 | -14.88 Million USD | -526.17% |
| 2003 | -2.37 Million USD | 60.84% |
| 2002 | -6.07 Million USD | 2.71% |
| 2001 | -6.23 Million USD | -58.67% |
| 2000 | -3.93 Million USD | -427.67% |
| 1999 | 1.2 Million USD | -55.56% |
| 1998 | 2.7 Million USD | 126.73% |
| 1997 | -10.1 Million USD | -215.63% |
| 1996 | -3.2 Million USD | -1166.67% |
| 1995 | 300 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 163.86 Million USD | -0.11% |
| 2024 Q1 | 164.04 Million USD | 8.86% |
| 2024 FY | 169.72 Million USD | 12.63% |
| 2024 Q4 | 169.72 Million USD | 2.48% |
| 2024 Q3 | 165.61 Million USD | 1.07% |
| 2023 FY | 150.69 Million USD | 167.38% |
| 2023 Q1 | 66.89 Million USD | 18.69% |
| 2023 Q2 | 104.09 Million USD | 55.62% |
| 2023 Q3 | 120.82 Million USD | 16.07% |
| 2023 Q4 | 150.69 Million USD | 24.72% |
| 2022 FY | 56.35 Million USD | 208.97% |
| 2022 Q1 | 4.58 Million USD | 108.86% |
| 2022 Q2 | 18.69 Million USD | 307.79% |
| 2022 Q3 | 32.88 Million USD | 75.88% |
| 2022 Q4 | 56.35 Million USD | 71.38% |
| 2021 FY | -51.72 Million USD | -449.59% |
| 2021 Q4 | -51.72 Million USD | -4.86% |
| 2021 Q3 | -49.32 Million USD | -257.75% |
| 2021 Q2 | -13.78 Million USD | -128.58% |
| 2021 Q1 | -6.03 Million USD | 35.9% |
| 2020 Q4 | -9.41 Million USD | -18.66% |
| 2020 FY | -9.41 Million USD | 70.83% |
| 2020 Q1 | -4.11 Million USD | 87.26% |
| 2020 Q2 | -10.32 Million USD | -151.16% |
| 2020 Q3 | -7.93 Million USD | 23.19% |
| 2019 Q4 | -32.25 Million USD | -16.6% |
| 2019 FY | -32.25 Million USD | 23.68% |
| 2019 Q1 | -37.39 Million USD | 11.53% |
| 2019 Q2 | -32.6 Million USD | 12.81% |
| 2019 Q3 | -27.66 Million USD | 15.14% |
| 2018 Q3 | -17.93 Million USD | 35.3% |
| 2018 Q4 | -42.26 Million USD | -135.62% |
| 2018 FY | -42.26 Million USD | 9.69% |
| 2018 Q1 | -37.25 Million USD | 20.39% |
| 2018 Q2 | -27.72 Million USD | 25.58% |
| 2017 Q3 | -41.52 Million USD | 15.34% |
| 2017 FY | -46.79 Million USD | 23.8% |
| 2017 Q1 | -44.19 Million USD | 28.04% |
| 2017 Q2 | -49.05 Million USD | -11.0% |
| 2017 Q4 | -46.79 Million USD | -12.69% |
| 2016 Q3 | -67.47 Million USD | 6.3% |
| 2016 Q4 | -61.41 Million USD | 8.98% |
| 2016 Q2 | -72 Million USD | -22.01% |
| 2016 Q1 | -59.01 Million USD | 13.21% |
| 2016 FY | -61.41 Million USD | 9.69% |
| 2015 FY | -68 Million USD | 12.25% |
| 2015 Q4 | -68 Million USD | -23.11% |
| 2015 Q1 | -73.25 Million USD | 5.46% |
| 2015 Q2 | -64.43 Million USD | 12.04% |
| 2015 Q3 | -55.23 Million USD | 14.28% |
| 2014 Q2 | -44.44 Million USD | -6.83% |
| 2014 Q4 | -77.49 Million USD | -22.66% |
| 2014 FY | -77.49 Million USD | -120.12% |
| 2014 Q1 | -41.6 Million USD | -18.17% |
| 2014 Q3 | -63.17 Million USD | -42.15% |
| 2013 FY | -35.2 Million USD | -95.22% |
| 2013 Q4 | -35.2 Million USD | -34.08% |
| 2013 Q3 | -26.25 Million USD | -7.41% |
| 2013 Q2 | -24.44 Million USD | -28.71% |
| 2013 Q1 | -18.99 Million USD | -5.31% |
| 2012 Q3 | -19.76 Million USD | -11.51% |
| 2012 Q1 | -15.71 Million USD | 27.78% |
| 2012 FY | -18.03 Million USD | 17.1% |
| 2012 Q2 | -17.72 Million USD | -12.8% |
| 2012 Q4 | -18.03 Million USD | 8.74% |
| 2011 Q1 | -15.32 Million USD | 6.97% |
| 2011 Q4 | -21.75 Million USD | 2.26% |
| 2011 FY | -21.75 Million USD | -32.06% |
| 2011 Q2 | -14.97 Million USD | 2.29% |
| 2011 Q3 | -22.25 Million USD | -48.64% |
| 2010 Q1 | -8.21 Million USD | -54.26% |
| 2010 FY | -16.47 Million USD | -209.41% |
| 2010 Q4 | -16.47 Million USD | -25.08% |
| 2010 Q3 | -13.17 Million USD | -37.24% |
| 2010 Q2 | -9.59 Million USD | -16.84% |
| 2009 Q4 | -5.32 Million USD | 14.24% |
| 2009 FY | -5.32 Million USD | 64.71% |
| 2009 Q3 | -6.2 Million USD | 24.08% |
| 2009 Q2 | -8.17 Million USD | 17.61% |
| 2009 Q1 | -9.92 Million USD | 34.21% |
| 2008 Q1 | -30.2 Million USD | -94.89% |
| 2008 FY | -15.08 Million USD | 2.66% |
| 2008 Q2 | -25.82 Million USD | 14.5% |
| 2008 Q3 | -20.02 Million USD | 22.45% |
| 2008 Q4 | -15.08 Million USD | 24.68% |
| 2007 FY | -15.49 Million USD | 4.29% |
| 2007 Q1 | -27.62 Million USD | -70.57% |
| 2007 Q3 | -19.45 Million USD | 14.0% |
| 2007 Q2 | -22.62 Million USD | 18.09% |
| 2007 Q4 | -15.49 Million USD | 20.33% |
| 2006 Q1 | -15.61 Million USD | -70.71% |
| 2006 FY | -16.19 Million USD | -77.01% |
| 2006 Q2 | -11.1 Million USD | 28.9% |
| 2006 Q4 | -16.19 Million USD | -9.57% |
| 2006 Q3 | -14.77 Million USD | -33.11% |
| 2005 Q3 | -9.71 Million USD | 5.91% |
| 2005 Q4 | -9.14 Million USD | 5.84% |
| 2005 Q2 | -10.32 Million USD | 13.64% |
| 2005 FY | -9.14 Million USD | 38.54% |
| 2005 Q1 | -11.95 Million USD | 19.67% |
| 2004 Q2 | -11.08 Million USD | -35.01% |
| 2004 Q4 | -14.88 Million USD | 5.44% |
| 2004 Q3 | -15.74 Million USD | -42.06% |
| 2004 Q1 | -8.2 Million USD | -245.27% |
| 2004 FY | -14.88 Million USD | -526.17% |
| 2003 Q2 | -5.05 Million USD | -115.67% |
| 2003 Q3 | -3.29 Million USD | 34.73% |
| 2003 Q4 | -2.37 Million USD | 27.9% |
| 2003 FY | -2.37 Million USD | 60.84% |
| 2003 Q1 | -2.34 Million USD | 61.42% |
| 2002 Q2 | -6.45 Million USD | 5.24% |
| 2002 Q1 | -6.8 Million USD | -9.12% |
| 2002 FY | -6.07 Million USD | 2.71% |
| 2002 Q4 | -6.07 Million USD | 45.43% |
| 2002 Q3 | -11.12 Million USD | -72.42% |
| 2001 Q4 | -6.23 Million USD | 9.87% |
| 2001 FY | -6.23 Million USD | -58.67% |
| 2001 Q3 | -6.92 Million USD | -183.92% |
| 2001 Q1 | -8.97 Million USD | -128.18% |
| 2001 Q2 | -2.43 Million USD | 72.83% |
| 2000 Q1 | 2 Million USD | 66.67% |
| 2000 Q2 | 2.9 Million USD | 45.0% |
| 2000 Q3 | 800 Thousand USD | -72.41% |
| 2000 Q4 | -3.93 Million USD | -591.5% |
| 2000 FY | -3.93 Million USD | -427.67% |
| 1999 FY | 1.2 Million USD | -55.56% |
| 1999 Q1 | -2.8 Million USD | -203.7% |
| 1999 Q2 | 400 Thousand USD | 114.29% |
| 1999 Q3 | 100 Thousand USD | -75.0% |
| 1999 Q4 | 1.2 Million USD | 1100.0% |
| 1998 FY | 2.7 Million USD | 126.73% |
| 1998 Q3 | -600 Thousand USD | 66.67% |
| 1998 Q4 | 2.7 Million USD | 550.0% |
| 1998 Q2 | -1.8 Million USD | 71.88% |
| 1998 Q1 | -6.4 Million USD | 36.63% |
| 1997 Q4 | -10.1 Million USD | -10000.0% |
| 1997 Q3 | -100 Thousand USD | 94.44% |
| 1997 FY | -10.1 Million USD | -215.63% |
| 1997 Q2 | -1.8 Million USD | 70.0% |
| 1997 Q1 | -6 Million USD | -87.5% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | -2.6 Million USD | 0.0% |
| 1996 FY | -3.2 Million USD | -1166.67% |
| 1996 Q4 | -3.2 Million USD | -23.08% |
| 1995 Q4 | 300 Thousand USD | 0.0% |
| 1995 FY | 300 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 403.411% |
| Alkermes plc | -166.73 Million USD | 201.793% |
| Agenus Inc. | 274.13 Million USD | 38.086% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 90.923% |
| Aptorum Group Limited | 1.35 Million USD | -12407.166% |
| Ardelyx, Inc. | 34.51 Million USD | -391.794% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -3865.607% |
| Bicycle Therapeutics plc | -481.46 Million USD | 135.252% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -369.342% |
| ChromaDex Corporation | -24.04 Million USD | 805.788% |
| Chimerix, Inc. | -25.51 Million USD | 765.157% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2335.794% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 816.848% |
| CRISPR Therapeutics AG | -150.84 Million USD | 212.518% |
| Precision BioSciences, Inc. | -85.41 Million USD | 298.721% |
| Dyadic International, Inc. | -6.37 Million USD | 2761.106% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 1165.261% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2114.325% |
| Lantern Pharma Inc. | -21.7 Million USD | 882.039% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 253.549% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 2086.708% |
| Incyte Corporation | -3.17 Billion USD | 105.346% |
| IO Biotech, Inc. | -140.69 Million USD | 220.632% |
| Jaguar Health, Inc. | 29.39 Million USD | -477.483% |
| Novavax, Inc. | -298.29 Million USD | 156.9% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -3080.214% |
| Opthea Limited | 28.15 Million USD | -502.782% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 1110.948% |
| ContextLogic Inc. | -232 Million USD | 173.159% |
| MiMedx Group, Inc. | -33.9 Million USD | 600.658% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -1564.816% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 7425.249% |
| NextCure, Inc. | -6.47 Million USD | 2720.472% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 436.088% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 2760.731% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -1295.415% |
| Vaxcyte, Inc. | -368.22 Million USD | 146.093% |
| PDS Biotechnology Corporation | -32.7 Million USD | 618.905% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -882.336% |
| Pharming Group N.V. | 109.8 Million USD | -54.574% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 1075.673% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 196.86% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1016.465% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 1016.465% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2490.535% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 2996.382% |
| Acelyrin, Inc. | -216.9 Million USD | 178.251% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 3125.311% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 9945.012% |
| Summit Therapeutics Inc. | 34.67 Million USD | -389.496% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 2594.899% |
| Senti Biosciences, Inc. | 1.74 Million USD | -9654.483% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 191.94% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 319.142% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 2899.868% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -170020.979% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -26926.752% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 245.01% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 200.889% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | -53.087% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 2334.439% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 231.456% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -2361.753% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 170.03% |
| Immix Biopharma, Inc. | -17.5 Million USD | 1069.332% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 153.592% |
| MEI Pharma, Inc. | -3.7 Million USD | 4681.053% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -1256.63% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | -4.937% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -510.686% |
| Fortress Biotech, Inc. | 7.66 Million USD | -2114.325% |
| Precigen, Inc. | -481 Thousand USD | 35386.486% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -1105.369% |
| AlloVir, Inc. | -62.69 Million USD | 370.733% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 405.189% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -175.238% |
| ImmuCell Corporation | 10.99 Million USD | -1444.307% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 210.109% |
| Onconetix, Inc. | 5.33 Million USD | -3083.532% |
| PureTech Health plc | -167.19 Million USD | 201.514% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 657.216% |
| Elevation Oncology, Inc. | -19.11 Million USD | 987.792% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 3557.486% |
| Seer, Inc. | -4.24 Million USD | 4103.019% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 806.111% |
| Innoviva, Inc. | 255.56 Million USD | 33.587% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 403.824% |
| ESSA Pharma Inc. | -33.62 Million USD | 604.819% |
| GlycoMimetics, Inc. | -40.98 Million USD | 514.128% |
| GT Biopharma, Inc. | -1.02 Million USD | 16723.702% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 350.399% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -177.075% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 226.588% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 1324.942% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 687.864% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 225400.661% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 649.958% |
| Aptose Biosciences Inc. | -8.19 Million USD | 2171.153% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 5524.322% |
| Soligenix, Inc. | -4.95 Million USD | 3527.743% |
| Century Therapeutics, Inc. | 847 Thousand USD | -19938.725% |
| Kura Oncology, Inc. | -20.11 Million USD | 943.662% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 514.719% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 2121.053% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -9217.037% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 5408.977% |
| Autolus Therapeutics plc | -186.59 Million USD | 190.959% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 444.248% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 161.542% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -395.296% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | -3.261% |
| GRI Bio, Inc. | -1.79 Million USD | 9560.87% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 1989.426% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 610.353% |
| IGM Biosciences, Inc. | -72.6 Million USD | 333.766% |
| INmune Bio, Inc. | -25.41 Million USD | 767.931% |
| Heron Therapeutics, Inc. | 150.95 Million USD | -12.439% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 435.04% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1144.52% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 5983.27% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -346.476% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 512.111% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -432.313% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 55.093% |
| Verastem, Inc. | -37.27 Million USD | 555.303% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 1970.693% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 427.269% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 1221.427% |
| Histogen Inc. | -7.48 Million USD | 2366.969% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 885.53% |
| Surrozen, Inc. | -32.66 Million USD | 619.618% |
| Organovo Holdings, Inc. | -1.5 Million USD | 11362.641% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 4137.79% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -795.18% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -6388.073% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -3983.927% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 2125.116% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 490.7% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 1264.366% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 153.578% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 23606.08% |
| Apollomics, Inc. | -27.39 Million USD | 719.558% |
| Amarin Corporation plc | -191.04 Million USD | 188.844% |
| Mesoblast Limited | 55.96 Million USD | -203.286% |
| Turnstone Biologics Corp. | -14.58 Million USD | 1263.796% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 771.074% |
| Synaptogenix, Inc. | -28.66 Million USD | 692.181% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 18233.333% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -248.289% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 19787.99% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 2435.895% |
| Exelixis, Inc. | -73.05 Million USD | 332.345% |
| Better Therapeutics, Inc. | -860 Thousand USD | 19835.814% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 806.817% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 170.318% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -22958.802% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 2381.862% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -13434.928% |
| Gritstone bio, Inc. | 39.49 Million USD | -329.8% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 301.814% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 6548.289% |
| Insmed Incorporated | 721.62 Million USD | 76.48% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 1956.673% |
| MediWound Ltd. | -5.32 Million USD | 3289.177% |
| OmniAb, Inc. | 9.2 Million USD | -1744.268% |
| Alector, Inc. | -35.63 Million USD | 576.269% |
| Seres Therapeutics, Inc. | 85.97 Million USD | -97.425% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 3544.156% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -1182.03% |
| Zai Lab Limited | -775 Million USD | 121.9% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 50.161% |
| Aura Biosciences, Inc. | -21.52 Million USD | 888.516% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 305.781% |
| Immunic, Inc. | -45.34 Million USD | 474.345% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 187.844% |
| Veracyte, Inc. | -203.82 Million USD | 183.272% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 73.409% |
| FibroGen, Inc. | 56.76 Million USD | -198.991% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1805.985% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 6103.646% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 8298.042% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 96.302% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 5180.156% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 202.268% |
| TG Therapeutics, Inc. | 17.86 Million USD | -850.218% |
| Galecto, Inc. | -21.21 Million USD | 900.0% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 813.593% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 89.185% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 793.56% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 1574.998% |
| XBiotech Inc. | -200.02 Million USD | 184.854% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 301.814% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -3648.41% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 581.32% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 319.804% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -2882.393% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 199.597% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 283.74% |
| Vaxxinity, Inc. | 10.13 Million USD | -1575.168% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 76.947% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 1676.292% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 357.335% |
| NexImmune, Inc. | -3.13 Million USD | 5516.316% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 5015.843% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 1223.175% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 726.303% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 1990.898% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 136345.635% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 518.338% |
| Ainos, Inc. | 4.07 Million USD | -4062.114% |
| Pluri Inc. | 22.82 Million USD | -643.475% |
| Prothena Corporation plc | -608.34 Million USD | 127.9% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 242.922% |
| Celularity Inc. | 65.19 Million USD | -160.359% |
| Rallybio Corporation | -24.1 Million USD | 804.207% |
| Cue Biopharma, Inc. | -33.81 Million USD | 601.872% |
| MeiraGTx Holdings plc | -40.3 Million USD | 521.14% |
| Omeros Corporation | 331.17 Million USD | 48.75% |
| Humacyte, Inc. | -22.48 Million USD | 854.816% |
| Immunocore Holdings plc | -358.59 Million USD | 147.332% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 790.653% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 649.264% |
| Blueprint Medicines Corporation | 702.83 Million USD | 75.851% |
| CalciMedica, Inc. | -5.53 Million USD | 3169.222% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 190.175% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 1761.719% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 523.928% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 610.414% |
| Pulmatrix, Inc. | -10.41 Million USD | 1729.337% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 2939.685% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 544.99% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 252.356% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 383.144% |
| Cytokinetics, Incorporated | 642.37 Million USD | 73.578% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 3014.786% |
| Nutriband Inc. | -251.65 Thousand USD | 67544.18% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 597.459% |
| Vor Biopharma Inc. | 4.3 Million USD | -3847.163% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 102.812% |
| Evogene Ltd. | -19.63 Million USD | 964.46% |
| ProKidney Corp. | -56.23 Million USD | 401.814% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 448.718% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 1937.443% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 87.556% |
| CorMedix Inc. | -43.05 Million USD | 494.235% |
| BioLineRx Ltd. | 7.33 Million USD | -2213.631% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 717.979% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -267.799% |
| Atai Life Sciences N.V. | -28.55 Million USD | 694.327% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -7509.316% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 843.899% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -857.023% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 326.081% |
| MediciNova, Inc. | -50.78 Million USD | 434.219% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 315.377% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 754614.337% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2730.386% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 184.94% |
| Biomea Fusion, Inc. | -166.57 Million USD | 201.896% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 194.833% |
| Mereo BioPharma Group plc | -51.46 Million USD | 429.767% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 278.955% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 157.778% |
| Absci Corporation | -72.59 Million USD | 333.792% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3617.214% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 172.398% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 280.157% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 277.362% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 534.387% |
| Allakos Inc. | -24.97 Million USD | 779.592% |
| Imunon, Inc. | -4.21 Million USD | 4127.859% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 1251.323% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 225.353% |
| BioAtla, Inc. | -109.01 Million USD | 255.698% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -22958.802% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 18175.399% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -1318.419% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 900.49% |
| XOMA Corporation | -29 Million USD | 685.269% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 1124.928% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1982.52% |
| aTyr Pharma, Inc. | -7.44 Million USD | 2378.534% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 236.179% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 181.536% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 307.545% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 282.97% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 19854.558% |
| Akari Therapeutics, Plc | -3.84 Million USD | 4514.252% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -10358.38% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 87.709% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 14385.245% |
| UroGen Pharma Ltd. | 4.39 Million USD | -3765.361% |
| Sutro Biopharma, Inc. | 113.48 Million USD | -49.565% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -235757.814% |
| Orgenesis Inc. | 21.78 Million USD | -679.141% |
| Entera Bio Ltd. | -10.62 Million USD | 1696.839% |
| GH Research PLC | -78.07 Million USD | 317.385% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 861.522% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 736.663% |
| Xencor, Inc. | 29.64 Million USD | -472.554% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 8716.457% |
| Replimune Group, Inc. | 1.41 Million USD | -11920.397% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 69402.759% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 234.26% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 14385.245% |
| Portage Biotech Inc. | -4.98 Million USD | 3507.509% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 754614.337% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 356.689% |
| OncoCyte Corporation | -6.56 Million USD | 2686.134% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -18813.031% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 3825.665% |
| Purple Biotech Ltd. | -14.13 Million USD | 1300.509% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 814.464% |
| scPharmaceuticals Inc. | -6.54 Million USD | 2693.247% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 1116.812% |
| HilleVax, Inc. | -165.48 Million USD | 202.564% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 6787.47% |
| Tharimmune, Inc. | -10.93 Million USD | 1652.104% |
| Genprex, Inc. | -6.73 Million USD | 2619.106% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 146.021% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 291.87% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 12214.775% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 5216.996% |
| OKYO Pharma Limited | -826.84 Thousand USD | 20627.11% |
| Savara Inc. | 153 Thousand USD | -110833.333% |
| Curis, Inc. | -23.88 Million USD | 810.545% |
| Daré Bioscience, Inc. | -5.15 Million USD | 3390.635% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 21971.827% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 2834.021% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -14223.038% |
| BeiGene, Ltd. | -2.25 Billion USD | 107.533% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -1275.597% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 127.906% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 191.455% |
| Erasca, Inc. | -37.21 Million USD | 556.062% |
| bluebird bio, Inc. | 108.57 Million USD | -56.329% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 13278.735% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 55.187% |
| DBV Technologies S.A. | -126.98 Million USD | 233.659% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 13278.735% |
| Moderna, Inc. | -2.9 Billion USD | 105.839% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 1739.567% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 1661.722% |
| Molecular Templates, Inc. | 707 Thousand USD | -23906.789% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 641.035% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 51.032% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 306.829% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 285.03% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 625.93% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 593.74% |
| MacroGenics, Inc. | -66.98 Million USD | 353.382% |
| RenovoRx, Inc. | -1.17 Million USD | 14569.565% |
| Adicet Bio, Inc. | -138.78 Million USD | 222.294% |
| Prime Medicine, Inc. | -27.94 Million USD | 707.451% |
| Aditxt, Inc. | 18.12 Million USD | -836.643% |
| Adagene Inc. | -87.62 Million USD | 293.693% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 4174.683% |
| Quantum-Si incorporated | -118.55 Million USD | 243.162% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -371.401% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 2370.855% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 449.89% |
| SciSparc Ltd. | -2.06 Million USD | 8319.274% |
| Vericel Corporation | 1.27 Million USD | -13191.151% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1515.379% |
| Minerva Neurosciences, Inc. | 41 Million USD | -313.928% |
| Generation Bio Co. | 31.44 Million USD | -439.71% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 196.786% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 648.873% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | -45.573% |
| Invivyd, Inc. | -198.47 Million USD | 185.516% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 288.023% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 7178.818% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 339.763% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 2586.857% |
| 2seventy bio, Inc. | 181.71 Million USD | 6.597% |
| ADMA Biologics, Inc. | 90.06 Million USD | -88.448% |
| Clene Inc. | 3.34 Million USD | -4981.677% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 1968.695% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 889.029% |
| GeoVax Labs, Inc. | -6.45 Million USD | 2730.386% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 149.322% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 752.808% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 4.468% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 4248.24% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -3293.203% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 3358.361% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 230.255% |
| Evaxion Biotech A/S | 5.28 Million USD | -3110.384% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 250.778% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 229.294% |
| Trevena, Inc. | 2.25 Million USD | -7416.74% |
| Surrozen, Inc. | -32.66 Million USD | 619.618% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 429.505% |
| Cingulate Inc. | 3.08 Million USD | -5405.853% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 5878.958% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2261.597% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 1926.755% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 313.971% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 229.118% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 260.816% |
| Clearmind Medicine Inc. | -3.94 Million USD | 4404.936% |
| Kronos Bio, Inc. | -36.05 Million USD | 570.761% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -1703.89% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -11540.138% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 412.828% |
| Statera Biopharma, Inc. | 14.41 Million USD | -1077.325% |
| ImmunityBio, Inc. | 618.22 Million USD | 72.546% |
| Korro Bio, Inc. | -132.94 Million USD | 227.67% |
| Kineta, Inc. | -4.54 Million USD | 3837.679% |
| BioVie Inc. | -17.73 Million USD | 1057.166% |
| Codexis, Inc. | -43.27 Million USD | 492.244% |
| Celularity Inc. | 65.19 Million USD | -160.359% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 5455.885% |
| Celcuity Inc. | 6.78 Million USD | -2402.068% |
| Virax Biolabs Group Limited | -3.36 Million USD | 5144.007% |
| Cibus, Inc. | -8.07 Million USD | 2201.114% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 4113.431% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -3613.961% |
| IN8bio, Inc. | -16.38 Million USD | 1135.621% |
| Kodiak Sciences Inc. | -103.87 Million USD | 263.396% |
| Annexon, Inc. | -193.75 Million USD | 187.599% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -471366.667% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 1069.93% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 4931.426% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 83.901% |
| Eyenovia, Inc. | 1.25 Million USD | -13384.367% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -530.842% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 5333.673% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 610.506% |
| Arcellx, Inc. | -296.95 Million USD | 157.156% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 970.132% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 388.285% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 918.874% |
| Moolec Science SA | 117.61 Thousand USD | -144206.897% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 542.012% |
| Geron Corporation | 14.76 Million USD | -1049.841% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 547.619% |
| Royalty Pharma plc | 5.65 Billion USD | 97.0% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 220.016% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 2528.355% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 3264.879% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 220.605% |
| Humacyte, Inc. | -22.48 Million USD | 854.816% |
| Structure Therapeutics Inc. | -124.33 Million USD | 236.504% |
| 89bio, Inc. | -289.05 Million USD | 158.719% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 772.403% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 9619.237% |
| Genelux Corporation | -6.89 Million USD | 2560.183% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 646.47% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | -103.026% |
| Notable Labs, Ltd. | -9.77 Million USD | 1836.17% |
| Liquidia Corporation | -80.17 Million USD | 311.694% |
| Mustang Bio, Inc. | -3.73 Million USD | 4643.041% |
| Immunovant, Inc. | -635.22 Million USD | 126.719% |
| Quantum-Si incorporated | -118.55 Million USD | 243.162% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 1066.34% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 4196.741% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -2014.464% |
| Acasti Pharma Inc. | -23 Million USD | 837.787% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 5140.584% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 1144.52% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 223.223% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 5546.351% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 863.44% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 1014.04% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 200.266% |
| PepGen Inc. | -60.67 Million USD | 379.756% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 838.719% |
| United Therapeutics Corporation | -507.7 Million USD | 133.431% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 987.42% |
| Solid Biosciences Inc. | -47.75 Million USD | 455.451% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 19787.99% |
| Immuneering Corporation | -54.94 Million USD | 408.917% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 4137.79% |
| Silo Pharma, Inc. | -3.52 Million USD | 4915.924% |
| Belite Bio, Inc | -87.27 Million USD | 294.484% |
| XOMA Corporation | -29 Million USD | 685.269% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 340.078% |
| Bionomics Limited | 227 Million USD | 25.233% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 245.962% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 6800.671% |
| uniQure N.V. | -102.95 Million USD | 264.863% |
| Cassava Sciences, Inc. | -121.13 Million USD | 240.114% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 4174.683% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -314.466% |
| Forte Biosciences, Inc. | -11.96 Million USD | 1519.012% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 5585.36% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -160020.755% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 5333.673% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -1805.985% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 2388.673% |
| Altimmune, Inc. | -134.48 Million USD | 226.204% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 14.307% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 6800.671% |
| Compugen Ltd. | -12.9 Million USD | 1415.313% |
| Peak Bio, Inc. | 10.34 Million USD | -1541.445% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 60074.558% |
| Benitec Biopharma Inc. | -50.58 Million USD | 435.55% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 262.671% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -763.976% |
| Zura Bio Limited | -99.8 Million USD | 270.058% |
| PolyPid Ltd. | 6.17 Million USD | -2650.859% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -128.991% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -763.976% |
| Instil Bio, Inc. | 75.35 Million USD | -125.229% |
| argenx SE | -2.02 Billion USD | 108.366% |
| Immunome, Inc. | -97.02 Million USD | 274.925% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 854.514% |
| Verona Pharma plc | -220.44 Million USD | 176.994% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 336.578% |
| Shattuck Labs, Inc. | -121.42 Million USD | 239.781% |
| CervoMed Inc. | -7.79 Million USD | 2277.998% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 191.498% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 3981.271% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 228.836% |
| Moolec Science SA | 117.61 Thousand USD | -144206.897% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 7518.256% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -967.58% |
| AnaptysBio, Inc. | -18.15 Million USD | 1035.089% |
| Design Therapeutics, Inc. | -18.15 Million USD | 1035.14% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 341.156% |
| NeurAxis, Inc. | 145.7 Thousand USD | -116391.421% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -1411.111% |
| Lumos Pharma, Inc. | -28.49 Million USD | 695.683% |
| Achilles Therapeutics plc | -126.92 Million USD | 233.724% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 336.578% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 25983.824% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 917.028% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -11540.138% |
| Nutriband Inc. | -251.65 Thousand USD | 67544.18% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 1388.649% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 2381.29% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 50.109% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -615.096% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 137.93% |
| Palisade Bio, Inc. | -12.06 Million USD | 1507.013% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 220.966% |
| Beam Therapeutics Inc. | -262.72 Million USD | 164.604% |
| Neurogene Inc. | -131.95 Million USD | 228.626% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -677.998% |
| AEON Biopharma, Inc. | -4.88 Million USD | 3578.033% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 144.998% |
| Sesen Bio, Inc. | -112.55 Million USD | 250.798% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 269.966% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 7329.257% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 534.91% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 303.799% |
| Athira Pharma, Inc. | -88.99 Million USD | 290.708% |
| Vaccinex, Inc. | -1.28 Million USD | 13277.64% |
| HCW Biologics Inc. | 2.85 Million USD | -5841.451% |
| XOMA Corporation | -29 Million USD | 685.269% |
| Nektar Therapeutics | 210.24 Million USD | 19.269% |
| Arvinas, Inc. | -313.8 Million USD | 154.088% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -10358.38% |
| Merus N.V. | -192.88 Million USD | 187.995% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -182.951% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 2546.353% |
| Rezolute, Inc. | -68.16 Million USD | 348.985% |
| Clene Inc. | 3.34 Million USD | -4981.677% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 1387.086% |
| BeyondSpring Inc. | -13.75 Million USD | 1333.937% |
| Synlogic, Inc. | -6.68 Million USD | 2638.938% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -14867.196% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 2107.428% |
| Peak Bio, Inc. | 10.34 Million USD | -1541.445% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 305.931% |
| Krystal Biotech, Inc. | -350.23 Million USD | 148.461% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | -36.74% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 200.433% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 5475.998% |
| MannKind Corporation | 143.89 Million USD | -17.949% |
| Ikena Oncology, Inc. | -109.15 Million USD | 255.491% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 2341.817% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 612.773% |
| Gossamer Bio, Inc. | 180.35 Million USD | 5.892% |
| CohBar, Inc. | -5.93 Million USD | 2961.839% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 670.553% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -3617.214% |
| Legend Biotech Corporation | -949.39 Million USD | 117.877% |
| Mural Oncology plc | -255.84 Million USD | 166.341% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -426.86% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 3703.076% |
| Disc Medicine, Inc. | -358.28 Million USD | 147.373% |
| Champions Oncology, Inc. | 4.81 Million USD | -3427.182% |
| REGENXBIO Inc. | 54.76 Million USD | -209.904% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 63217.732% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 212.385% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 1983.354% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 310.364% |
| Vaxart, Inc. | -8.24 Million USD | 2159.556% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 438.239% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 233.47% |
| Cellectis S.A. | -43.85 Million USD | 487.021% |
| Longeveron Inc. | -2.9 Million USD | 5936.589% |
| Repare Therapeutics Inc. | -107.85 Million USD | 257.362% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 82.473% |
| Inozyme Pharma, Inc. | 12 Million USD | -1313.929% |
| Revolution Medicines, Inc. | -608.2 Million USD | 127.906% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 13899.024% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 164.02% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 213.098% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 1184.732% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 23036.216% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.775% |
| Denali Therapeutics Inc. | -74.86 Million USD | 326.712% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 1515.379% |
| Veru Inc. | 4.77 Million USD | -3450.818% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 1609.23% |
| Cingulate Inc. | 3.08 Million USD | -5405.853% |
| Passage Bio, Inc. | 4.58 Million USD | -3601.81% |
| Context Therapeutics Inc. | -14.44 Million USD | 1274.602% |
| Exicure, Inc. | 5.84 Million USD | -2801.829% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 173.674% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 528.931% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -981.69% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 388.55% |
| Nuvalent, Inc. | -335.38 Million USD | 150.607% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -9686.311% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 327.878% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 2009.201% |
| OmniAb, Inc. | 9.2 Million USD | -1744.268% |
| Anew Medical, Inc. | 1.43 Million USD | -11748.666% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -936.079% |
| Lipocine Inc. | -4.75 Million USD | 3669.77% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 254.54% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -1014.359% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 435.04% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -581.858% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 2625.338% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 357.839% |
| Ocugen, Inc. | -32.52 Million USD | 621.903% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 298.338% |
| Q32 Bio Inc. | -37.94 Million USD | 547.265% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 27126.752% |
| Alumis Inc. Common Stock | -13.52 Million USD | 1354.549% |
| Equillium, Inc. | -22.39 Million USD | 857.985% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 763.83% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 620.211% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 68562.175% |
| Galera Therapeutics, Inc. | 134.04 Million USD | -26.623% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -5207.317% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -51576.861% |
| Dominari Holdings Inc. | 195 Thousand USD | -86940.0% |
| Edesa Biotech, Inc. | -5.26 Million USD | 3322.535% |
| vTv Therapeutics Inc. | -8.91 Million USD | 2003.42% |
| Bio-Techne Corporation | 267.74 Million USD | 36.609% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 1147.122% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 243.723% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 2119.85% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 1441.617% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 169.243% |
| Nkarta, Inc. | 57.29 Million USD | -196.215% |
| BioCardia, Inc. | 212 Thousand USD | -79960.377% |
| Iterum Therapeutics plc | 13.43 Million USD | -1163.045% |